Display options
Cite
Kessler HA. Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review. J Int AIDS Soc. 2005;7(2):70doi: 10.1186/1758-2652-7-2-70.
Kessler, H. A. (2005). Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review. Journal of the International AIDS Society, 7(2), 70. https://doi.org/10.1186/1758-2652-7-2-70
Kessler, Harold A. "Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review." Journal of the International AIDS Society vol. 7,2 (2005): 70. doi: https://doi.org/10.1186/1758-2652-7-2-70
Kessler HA. Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review. J Int AIDS Soc. 2005 Jun 02;7(2):70. doi: 10.1186/1758-2652-7-2-70. PMID: 19825128; PMCID: PMC2740786.
Copy Download .nbib Format: NLM
Share it on

J Int AIDS Soc. 2005 Jun 02;7(2):70. doi: 10.1186/1758-2652-7-2-70.

Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review.

Journal of the International AIDS Society

Harold A Kessler

Affiliations

  1. Professor of Medicine and Immunology/Microbiology, Associate Director, Section of Infectious Diseases, Rush University Medical Center, Chicago, Illinois. [email protected].

PMID: 19825128 PMCID: PMC2740786 DOI: 10.1186/1758-2652-7-2-70

Abstract

The development and widespread clinical use of coformulated abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) as Trizivir represented an important advance in the management of HIV-infected patients, especially those with adherence challenges. With a low pill burden, no food restrictions, limited drug-drug interactions, and a favorable resistance profile, ABC/3TC/ZDV remains an alternative option in the US Department of Health and Human Services Consensus Panel Guidelines as initial treatment in antiretroviral-naive patients. Recent data have shown ABC/3TC/ZDV to be less efficacious in suppressing and/or maintaining suppression of virologic replication compared with efavirenz-containing antiretroviral therapy. Although triple-nucleoside/nucleotide reverse transcriptase inhibitor (t-NRTI) combinations that do not contain a thymidine analog (ZDV or stavudine) have recently shown high virologic failure rates in clinical trials and clinical practice, t-NRTI regimens containing a thymidine analog have consistently been shown to be efficacious.

References

  1. AIDS. 2002 May 3;16(7):1086-7 - PubMed
  2. Lancet. 2003 Dec 13;362(9400):1979-80 - PubMed
  3. JAMA. 2001 Mar 7;285(9):1155-63 - PubMed
  4. AIDS. 2001 Aug 17;15(12):1517-26 - PubMed
  5. Curr Med Res Opin. 2004 Jul;20(7):1103-14 - PubMed
  6. Hopkins HIV Rep. 1999 Jul;11(4):9-12 - PubMed
  7. N Engl J Med. 2004 Apr 29;350(18):1850-61 - PubMed
  8. N Engl J Med. 2003 Sep 11;349(11):1036-46 - PubMed
  9. HIV Med. 2003 Apr;4(2):79-86 - PubMed

Publication Types